The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
The global CD47 (IAP) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for CD47 (IAP) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for CD47 (IAP) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for CD47 (IAP) in Solid Tumor is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of CD47 (IAP) include Gilead, Innovent Biologics, Akeso, Inc, Arch Oncology, ImmuneOncia Therapeutics, I-MAB, Sorrento Therapeutics, Zai Lab and ImmuneOnco, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for CD47 (IAP), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CD47 (IAP).
Report Scope
The CD47 (IAP) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global CD47 (IAP) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the CD47 (IAP) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Gilead
Innovent Biologics
Akeso, Inc
Arch Oncology
ImmuneOncia Therapeutics
I-MAB
Sorrento Therapeutics
Zai Lab
ImmuneOnco
Hengrui
Beijing Mab-works
Hanxbio
ALX Oncology
Surface Oncology
TG Therapeutics
EpicentRx
Segment by Type
CD47 Monoclonal Antibody
CD47 Double Antibody
CD47 Fusion Protein
Segment by Application
Solid Tumor
Lymphoma
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of CD47 (IAP) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global CD47 (IAP) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for CD47 (IAP) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for CD47 (IAP) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for CD47 (IAP) in Solid Tumor is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of CD47 (IAP) include Gilead, Innovent Biologics, Akeso, Inc, Arch Oncology, ImmuneOncia Therapeutics, I-MAB, Sorrento Therapeutics, Zai Lab and ImmuneOnco, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for CD47 (IAP), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CD47 (IAP).
Report Scope
The CD47 (IAP) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global CD47 (IAP) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the CD47 (IAP) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Gilead
Innovent Biologics
Akeso, Inc
Arch Oncology
ImmuneOncia Therapeutics
I-MAB
Sorrento Therapeutics
Zai Lab
ImmuneOnco
Hengrui
Beijing Mab-works
Hanxbio
ALX Oncology
Surface Oncology
TG Therapeutics
EpicentRx
Segment by Type
CD47 Monoclonal Antibody
CD47 Double Antibody
CD47 Fusion Protein
Segment by Application
Solid Tumor
Lymphoma
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of CD47 (IAP) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global CD47 (IAP) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 CD47 Monoclonal Antibody
1.2.3 CD47 Double Antibody
1.2.4 CD47 Fusion Protein
1.3 Market by Application
1.3.1 Global CD47 (IAP) Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Solid Tumor
1.3.3 Lymphoma
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global CD47 (IAP) Market Perspective (2019-2030)
2.2 CD47 (IAP) Growth Trends by Region
2.2.1 Global CD47 (IAP) Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 CD47 (IAP) Historic Market Size by Region (2019-2024)
2.2.3 CD47 (IAP) Forecasted Market Size by Region (2025-2030)
2.3 CD47 (IAP) Market Dynamics
2.3.1 CD47 (IAP) Industry Trends
2.3.2 CD47 (IAP) Market Drivers
2.3.3 CD47 (IAP) Market Challenges
2.3.4 CD47 (IAP) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top CD47 (IAP) Players by Revenue
3.1.1 Global Top CD47 (IAP) Players by Revenue (2019-2024)
3.1.2 Global CD47 (IAP) Revenue Market Share by Players (2019-2024)
3.2 Global CD47 (IAP) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by CD47 (IAP) Revenue
3.4 Global CD47 (IAP) Market Concentration Ratio
3.4.1 Global CD47 (IAP) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by CD47 (IAP) Revenue in 2023
3.5 CD47 (IAP) Key Players Head office and Area Served
3.6 Key Players CD47 (IAP) Product Solution and Service
3.7 Date of Enter into CD47 (IAP) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 CD47 (IAP) Breakdown Data by Type
4.1 Global CD47 (IAP) Historic Market Size by Type (2019-2024)
4.2 Global CD47 (IAP) Forecasted Market Size by Type (2025-2030)
5 CD47 (IAP) Breakdown Data by Application
5.1 Global CD47 (IAP) Historic Market Size by Application (2019-2024)
5.2 Global CD47 (IAP) Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America CD47 (IAP) Market Size (2019-2030)
6.2 North America CD47 (IAP) Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America CD47 (IAP) Market Size by Country (2019-2024)
6.4 North America CD47 (IAP) Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe CD47 (IAP) Market Size (2019-2030)
7.2 Europe CD47 (IAP) Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe CD47 (IAP) Market Size by Country (2019-2024)
7.4 Europe CD47 (IAP) Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific CD47 (IAP) Market Size (2019-2030)
8.2 Asia-Pacific CD47 (IAP) Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific CD47 (IAP) Market Size by Region (2019-2024)
8.4 Asia-Pacific CD47 (IAP) Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America CD47 (IAP) Market Size (2019-2030)
9.2 Latin America CD47 (IAP) Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America CD47 (IAP) Market Size by Country (2019-2024)
9.4 Latin America CD47 (IAP) Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa CD47 (IAP) Market Size (2019-2030)
10.2 Middle East & Africa CD47 (IAP) Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa CD47 (IAP) Market Size by Country (2019-2024)
10.4 Middle East & Africa CD47 (IAP) Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Gilead
11.1.1 Gilead Company Detail
11.1.2 Gilead Business Overview
11.1.3 Gilead CD47 (IAP) Introduction
11.1.4 Gilead Revenue in CD47 (IAP) Business (2019-2024)
11.1.5 Gilead Recent Development
11.2 Innovent Biologics
11.2.1 Innovent Biologics Company Detail
11.2.2 Innovent Biologics Business Overview
11.2.3 Innovent Biologics CD47 (IAP) Introduction
11.2.4 Innovent Biologics Revenue in CD47 (IAP) Business (2019-2024)
11.2.5 Innovent Biologics Recent Development
11.3 Akeso, Inc
11.3.1 Akeso, Inc Company Detail
11.3.2 Akeso, Inc Business Overview
11.3.3 Akeso, Inc CD47 (IAP) Introduction
11.3.4 Akeso, Inc Revenue in CD47 (IAP) Business (2019-2024)
11.3.5 Akeso, Inc Recent Development
11.4 Arch Oncology
11.4.1 Arch Oncology Company Detail
11.4.2 Arch Oncology Business Overview
11.4.3 Arch Oncology CD47 (IAP) Introduction
11.4.4 Arch Oncology Revenue in CD47 (IAP) Business (2019-2024)
11.4.5 Arch Oncology Recent Development
11.5 ImmuneOncia Therapeutics
11.5.1 ImmuneOncia Therapeutics Company Detail
11.5.2 ImmuneOncia Therapeutics Business Overview
11.5.3 ImmuneOncia Therapeutics CD47 (IAP) Introduction
11.5.4 ImmuneOncia Therapeutics Revenue in CD47 (IAP) Business (2019-2024)
11.5.5 ImmuneOncia Therapeutics Recent Development
11.6 I-MAB
11.6.1 I-MAB Company Detail
11.6.2 I-MAB Business Overview
11.6.3 I-MAB CD47 (IAP) Introduction
11.6.4 I-MAB Revenue in CD47 (IAP) Business (2019-2024)
11.6.5 I-MAB Recent Development
11.7 Sorrento Therapeutics
11.7.1 Sorrento Therapeutics Company Detail
11.7.2 Sorrento Therapeutics Business Overview
11.7.3 Sorrento Therapeutics CD47 (IAP) Introduction
11.7.4 Sorrento Therapeutics Revenue in CD47 (IAP) Business (2019-2024)
11.7.5 Sorrento Therapeutics Recent Development
11.8 Zai Lab
11.8.1 Zai Lab Company Detail
11.8.2 Zai Lab Business Overview
11.8.3 Zai Lab CD47 (IAP) Introduction
11.8.4 Zai Lab Revenue in CD47 (IAP) Business (2019-2024)
11.8.5 Zai Lab Recent Development
11.9 ImmuneOnco
11.9.1 ImmuneOnco Company Detail
11.9.2 ImmuneOnco Business Overview
11.9.3 ImmuneOnco CD47 (IAP) Introduction
11.9.4 ImmuneOnco Revenue in CD47 (IAP) Business (2019-2024)
11.9.5 ImmuneOnco Recent Development
11.10 Hengrui
11.10.1 Hengrui Company Detail
11.10.2 Hengrui Business Overview
11.10.3 Hengrui CD47 (IAP) Introduction
11.10.4 Hengrui Revenue in CD47 (IAP) Business (2019-2024)
11.10.5 Hengrui Recent Development
11.11 Beijing Mab-works
11.11.1 Beijing Mab-works Company Detail
11.11.2 Beijing Mab-works Business Overview
11.11.3 Beijing Mab-works CD47 (IAP) Introduction
11.11.4 Beijing Mab-works Revenue in CD47 (IAP) Business (2019-2024)
11.11.5 Beijing Mab-works Recent Development
11.12 Hanxbio
11.12.1 Hanxbio Company Detail
11.12.2 Hanxbio Business Overview
11.12.3 Hanxbio CD47 (IAP) Introduction
11.12.4 Hanxbio Revenue in CD47 (IAP) Business (2019-2024)
11.12.5 Hanxbio Recent Development
11.13 ALX Oncology
11.13.1 ALX Oncology Company Detail
11.13.2 ALX Oncology Business Overview
11.13.3 ALX Oncology CD47 (IAP) Introduction
11.13.4 ALX Oncology Revenue in CD47 (IAP) Business (2019-2024)
11.13.5 ALX Oncology Recent Development
11.14 Surface Oncology
11.14.1 Surface Oncology Company Detail
11.14.2 Surface Oncology Business Overview
11.14.3 Surface Oncology CD47 (IAP) Introduction
11.14.4 Surface Oncology Revenue in CD47 (IAP) Business (2019-2024)
11.14.5 Surface Oncology Recent Development
11.15 TG Therapeutics
11.15.1 TG Therapeutics Company Detail
11.15.2 TG Therapeutics Business Overview
11.15.3 TG Therapeutics CD47 (IAP) Introduction
11.15.4 TG Therapeutics Revenue in CD47 (IAP) Business (2019-2024)
11.15.5 TG Therapeutics Recent Development
11.16 EpicentRx
11.16.1 EpicentRx Company Detail
11.16.2 EpicentRx Business Overview
11.16.3 EpicentRx CD47 (IAP) Introduction
11.16.4 EpicentRx Revenue in CD47 (IAP) Business (2019-2024)
11.16.5 EpicentRx Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global CD47 (IAP) Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of CD47 Monoclonal Antibody
Table 3. Key Players of CD47 Double Antibody
Table 4. Key Players of CD47 Fusion Protein
Table 5. Global CD47 (IAP) Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global CD47 (IAP) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global CD47 (IAP) Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global CD47 (IAP) Market Share by Region (2019-2024)
Table 9. Global CD47 (IAP) Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global CD47 (IAP) Market Share by Region (2025-2030)
Table 11. CD47 (IAP) Market Trends
Table 12. CD47 (IAP) Market Drivers
Table 13. CD47 (IAP) Market Challenges
Table 14. CD47 (IAP) Market Restraints
Table 15. Global CD47 (IAP) Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global CD47 (IAP) Market Share by Players (2019-2024)
Table 17. Global Top CD47 (IAP) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CD47 (IAP) as of 2023)
Table 18. Ranking of Global Top CD47 (IAP) Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by CD47 (IAP) Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players CD47 (IAP) Product Solution and Service
Table 22. Date of Enter into CD47 (IAP) Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global CD47 (IAP) Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global CD47 (IAP) Revenue Market Share by Type (2019-2024)
Table 26. Global CD47 (IAP) Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global CD47 (IAP) Revenue Market Share by Type (2025-2030)
Table 28. Global CD47 (IAP) Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global CD47 (IAP) Revenue Market Share by Application (2019-2024)
Table 30. Global CD47 (IAP) Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global CD47 (IAP) Revenue Market Share by Application (2025-2030)
Table 32. North America CD47 (IAP) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America CD47 (IAP) Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America CD47 (IAP) Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe CD47 (IAP) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe CD47 (IAP) Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe CD47 (IAP) Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific CD47 (IAP) Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific CD47 (IAP) Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific CD47 (IAP) Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America CD47 (IAP) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America CD47 (IAP) Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America CD47 (IAP) Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa CD47 (IAP) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa CD47 (IAP) Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa CD47 (IAP) Market Size by Country (2025-2030) & (US$ Million)
Table 47. Gilead Company Detail
Table 48. Gilead Business Overview
Table 49. Gilead CD47 (IAP) Product
Table 50. Gilead Revenue in CD47 (IAP) Business (2019-2024) & (US$ Million)
Table 51. Gilead Recent Development
Table 52. Innovent Biologics Company Detail
Table 53. Innovent Biologics Business Overview
Table 54. Innovent Biologics CD47 (IAP) Product
Table 55. Innovent Biologics Revenue in CD47 (IAP) Business (2019-2024) & (US$ Million)
Table 56. Innovent Biologics Recent Development
Table 57. Akeso, Inc Company Detail
Table 58. Akeso, Inc Business Overview
Table 59. Akeso, Inc CD47 (IAP) Product
Table 60. Akeso, Inc Revenue in CD47 (IAP) Business (2019-2024) & (US$ Million)
Table 61. Akeso, Inc Recent Development
Table 62. Arch Oncology Company Detail
Table 63. Arch Oncology Business Overview
Table 64. Arch Oncology CD47 (IAP) Product
Table 65. Arch Oncology Revenue in CD47 (IAP) Business (2019-2024) & (US$ Million)
Table 66. Arch Oncology Recent Development
Table 67. ImmuneOncia Therapeutics Company Detail
Table 68. ImmuneOncia Therapeutics Business Overview
Table 69. ImmuneOncia Therapeutics CD47 (IAP) Product
Table 70. ImmuneOncia Therapeutics Revenue in CD47 (IAP) Business (2019-2024) & (US$ Million)
Table 71. ImmuneOncia Therapeutics Recent Development
Table 72. I-MAB Company Detail
Table 73. I-MAB Business Overview
Table 74. I-MAB CD47 (IAP) Product
Table 75. I-MAB Revenue in CD47 (IAP) Business (2019-2024) & (US$ Million)
Table 76. I-MAB Recent Development
Table 77. Sorrento Therapeutics Company Detail
Table 78. Sorrento Therapeutics Business Overview
Table 79. Sorrento Therapeutics CD47 (IAP) Product
Table 80. Sorrento Therapeutics Revenue in CD47 (IAP) Business (2019-2024) & (US$ Million)
Table 81. Sorrento Therapeutics Recent Development
Table 82. Zai Lab Company Detail
Table 83. Zai Lab Business Overview
Table 84. Zai Lab CD47 (IAP) Product
Table 85. Zai Lab Revenue in CD47 (IAP) Business (2019-2024) & (US$ Million)
Table 86. Zai Lab Recent Development
Table 87. ImmuneOnco Company Detail
Table 88. ImmuneOnco Business Overview
Table 89. ImmuneOnco CD47 (IAP) Product
Table 90. ImmuneOnco Revenue in CD47 (IAP) Business (2019-2024) & (US$ Million)
Table 91. ImmuneOnco Recent Development
Table 92. Hengrui Company Detail
Table 93. Hengrui Business Overview
Table 94. Hengrui CD47 (IAP) Product
Table 95. Hengrui Revenue in CD47 (IAP) Business (2019-2024) & (US$ Million)
Table 96. Hengrui Recent Development
Table 97. Beijing Mab-works Company Detail
Table 98. Beijing Mab-works Business Overview
Table 99. Beijing Mab-works CD47 (IAP) Product
Table 100. Beijing Mab-works Revenue in CD47 (IAP) Business (2019-2024) & (US$ Million)
Table 101. Beijing Mab-works Recent Development
Table 102. Hanxbio Company Detail
Table 103. Hanxbio Business Overview
Table 104. Hanxbio CD47 (IAP) Product
Table 105. Hanxbio Revenue in CD47 (IAP) Business (2019-2024) & (US$ Million)
Table 106. Hanxbio Recent Development
Table 107. ALX Oncology Company Detail
Table 108. ALX Oncology Business Overview
Table 109. ALX Oncology CD47 (IAP) Product
Table 110. ALX Oncology Revenue in CD47 (IAP) Business (2019-2024) & (US$ Million)
Table 111. ALX Oncology Recent Development
Table 112. Surface Oncology Company Detail
Table 113. Surface Oncology Business Overview
Table 114. Surface Oncology CD47 (IAP) Product
Table 115. Surface Oncology Revenue in CD47 (IAP) Business (2019-2024) & (US$ Million)
Table 116. Surface Oncology Recent Development
Table 117. TG Therapeutics Company Detail
Table 118. TG Therapeutics Business Overview
Table 119. TG Therapeutics CD47 (IAP) Product
Table 120. TG Therapeutics Revenue in CD47 (IAP) Business (2019-2024) & (US$ Million)
Table 121. TG Therapeutics Recent Development
Table 122. EpicentRx Company Detail
Table 123. EpicentRx Business Overview
Table 124. EpicentRx CD47 (IAP) Product
Table 125. EpicentRx Revenue in CD47 (IAP) Business (2019-2024) & (US$ Million)
Table 126. EpicentRx Recent Development
Table 127. Research Programs/Design for This Report
Table 128. Key Data Information from Secondary Sources
Table 129. Key Data Information from Primary Sources
List of Figures
Figure 1. Global CD47 (IAP) Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global CD47 (IAP) Market Share by Type: 2023 VS 2030
Figure 3. CD47 Monoclonal Antibody Features
Figure 4. CD47 Double Antibody Features
Figure 5. CD47 Fusion Protein Features
Figure 6. Global CD47 (IAP) Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global CD47 (IAP) Market Share by Application: 2023 VS 2030
Figure 8. Solid Tumor Case Studies
Figure 9. Lymphoma Case Studies
Figure 10. Others Case Studies
Figure 11. CD47 (IAP) Report Years Considered
Figure 12. Global CD47 (IAP) Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global CD47 (IAP) Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global CD47 (IAP) Market Share by Region: 2023 VS 2030
Figure 15. Global CD47 (IAP) Market Share by Players in 2023
Figure 16. Global Top CD47 (IAP) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CD47 (IAP) as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by CD47 (IAP) Revenue in 2023
Figure 18. North America CD47 (IAP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America CD47 (IAP) Market Share by Country (2019-2030)
Figure 20. United States CD47 (IAP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada CD47 (IAP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe CD47 (IAP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe CD47 (IAP) Market Share by Country (2019-2030)
Figure 24. Germany CD47 (IAP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France CD47 (IAP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. CD47 (IAP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy CD47 (IAP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia CD47 (IAP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries CD47 (IAP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific CD47 (IAP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific CD47 (IAP) Market Share by Region (2019-2030)
Figure 32. China CD47 (IAP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan CD47 (IAP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea CD47 (IAP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia CD47 (IAP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India CD47 (IAP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia CD47 (IAP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America CD47 (IAP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America CD47 (IAP) Market Share by Country (2019-2030)
Figure 40. Mexico CD47 (IAP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil CD47 (IAP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa CD47 (IAP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa CD47 (IAP) Market Share by Country (2019-2030)
Figure 44. Turkey CD47 (IAP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia CD47 (IAP) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Gilead Revenue Growth Rate in CD47 (IAP) Business (2019-2024)
Figure 47. Innovent Biologics Revenue Growth Rate in CD47 (IAP) Business (2019-2024)
Figure 48. Akeso, Inc Revenue Growth Rate in CD47 (IAP) Business (2019-2024)
Figure 49. Arch Oncology Revenue Growth Rate in CD47 (IAP) Business (2019-2024)
Figure 50. ImmuneOncia Therapeutics Revenue Growth Rate in CD47 (IAP) Business (2019-2024)
Figure 51. I-MAB Revenue Growth Rate in CD47 (IAP) Business (2019-2024)
Figure 52. Sorrento Therapeutics Revenue Growth Rate in CD47 (IAP) Business (2019-2024)
Figure 53. Zai Lab Revenue Growth Rate in CD47 (IAP) Business (2019-2024)
Figure 54. ImmuneOnco Revenue Growth Rate in CD47 (IAP) Business (2019-2024)
Figure 55. Hengrui Revenue Growth Rate in CD47 (IAP) Business (2019-2024)
Figure 56. Beijing Mab-works Revenue Growth Rate in CD47 (IAP) Business (2019-2024)
Figure 57. Hanxbio Revenue Growth Rate in CD47 (IAP) Business (2019-2024)
Figure 58. ALX Oncology Revenue Growth Rate in CD47 (IAP) Business (2019-2024)
Figure 59. Surface Oncology Revenue Growth Rate in CD47 (IAP) Business (2019-2024)
Figure 60. TG Therapeutics Revenue Growth Rate in CD47 (IAP) Business (2019-2024)
Figure 61. EpicentRx Revenue Growth Rate in CD47 (IAP) Business (2019-2024)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
